Atherosclerosis
Volume 207, Issue 1 , Pages 16-23 , November 2009

Where are we with probucol: A new life for an old drug?

  • Shizuya Yamashita

      Affiliations

    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 66879 3732; fax: +81 66879 3739.
    • ,
  • Yuji Matsuzawa

      Affiliations

    • Sumitomo Hospital, Osaka, Japan

Received 28 November 2008 ,Revised 2 April 2009 ,Accepted 2 April 2009.

References 

  1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267–1278
  2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  3. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375–2414
  4. Superko HR, King S. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation. 2008;117:560–568[discussion 8]
  5. Yamashita S, Bujo H, Arai H, et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2008;15:292–303
  6. Yamamoto A. A uniqe antilipidemic drug—probucol. J Atheroscler Thromb. 2008;15:304–305
  7. Sirtori CR, Mombelli G. Viability of developing CETP inhibitors. Cardiovas Therap. 2008;26:135–146
  8. Barnhart JW, Sefranka JA, McIntosh DD. Hypocholesterolemic effect of 4, 4′-(isopropylidenedithio)-bis (2,6-di-t-butylphenol) (probucol). Am J Clin Nutr. 1970;23:1229–1233
  9. Fruebis J, Gonzalez V, Silvestre M, Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17:1289–1302
  10. Brasen JH, Koenig K, Bach H, et al. Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. Atherosclerosis. 2002;163:249–259
  11. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046–1051
  12. Lau AK, Leichtweis SB, Hume P, et al. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation. 2003;107:2031–2036
  13. Witting PK, Wu BJ, Raftery M, Southwell-Keely P, Stocker R. Probucol protects against hypochlorite-induced endothelial dysfunction. Identification of a novel pathway of probucol oxidation to a biologically active intermediate. J Biol Chem. 2005;280:15612–15618
  14. Wu BJ, Kathir K, Witting PK, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med. 2006;203:1117–1127
  15. Alam J, Stewart D, Touchard C, et al. Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem. 1999;274:26071–26078
  16. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA. 1987;84:5928–5931
  17. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924
  18. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?. J Clin Invest. 1994;94:155–164
  19. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381–1478
  20. Witting PK, Pettersson K, Ostlund-Lindqvist A-M, et al. Dissociation of atherogenesis from aortic accumulation of lipid hydro(per)oxides in Watanabe heritable hyperlipidemic rabbits. J Clin Invest. 1999;104:213–220
  21. Franceschini G, Sirtori M, Vaccarino V, et al. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis. 1989;9:462–469
  22. Ishigami M, Yamashita S, Sakai N, et al. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 1997;27:285–292
  23. Hirano K, Ikegami C, Tsujii K, et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol. 2005;25:2422–2427
  24. Miida T, Seino U, Miyazaki O, et al. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis. 2008;200:329–335
  25. Favari E, Zanotti I, Zimetti F, et al. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol. 2004;24:2345–2350
  26. Moghadasian MH. Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice. Atherosclerosis. 2006;188:28–34
  27. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122
  28. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053–1059
  29. Nagano M, Yamashita S, Hirano K, et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb. 2004;11:110–121
  30. Matsuzawa Y, Yamashita S, Kameda K, et al. Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report. Atherosclerosis. 1984;53:207–212
  31. Cazita PM, Barbeiro DF, Moretti AI, Quintão EC, Soriano FG. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock. 2008;30:590–595
  32. Thompson JF, Reynolds JM, Williams SP, et al. Frequency and function of CETP variants among individuals of Asian ancestry. Atherosclerosis. 2009;202:241–247
  33. Braun A, Zhang S, Miettinen HE, et al. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci USA. 2003;100:7283–7288
  34. Ferns GA, Forster L, Stewart-Lee A, et al. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci USA. 1992;89:11312–11316
  35. Tanaka K, Hayashi K, Shingu T, et al. Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells. Cardiovasc Drugs Ther. 1998;12:19–28
  36. Yang YB, Yang YX, Su B, et al. Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway. Eur J Pharmacol. 2007;570:125–134
  37. Wu BJ, Di Girolamo N, Beck K, et al. Probucol[4,4′-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 2007;321:477–484
  38. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 1998;82:144–147
  39. Park SY, Lee JH, Kim CD, et al. Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res. 2007;1157:112–120
  40. Yoshikawa T, Mitani K, Kotosai K, et al. Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Horm Metab Res. 2008;40:473–478
  41. Umehara K, Shimokawa Y, Miyamoto G. Effect of probucol on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull. 2002;25:1112–1114
  42. Matsuzawa Y, Yamashita S, Funahashi T, Yamamoto A, Tarui S. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol. 1988;62:66B–72B
  43. Yamamoto A, Hara H, Takaichi S, Wakasugi J, Tomikawa M. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol. 1988;62:31B–36B
  44. Nakamura T, Ueyama Y, Funahashi T, et al. Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases. Atherosclerosis. 1992;92:193–202
  45. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral Atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol. 1994;74:875–883
  46. Tardif JC, Cote G, Lesperance J, et al. Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol. 2001;17:49–55
  47. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 2002;39:610–616
  48. Tardif JC, Gregoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 2003;107:552–558
  49. Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:1761–1768
  50. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2003;45:415–427
  51. Guo J, Massaeli H, Li W, et al. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther. 2007;321:911–920
  52. Tamura M, Ueki Y, Ohtsuka E, et al. Probucol-induced QT prolongation and syncope. Jpn Circ J. 1994;58:374–377
  53. Arai T, Wang N, Bezouevski M, et al. Decrease atherosclerosis on heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem. 1999;274:2366–2371
  54. Yokoi H, Daida T, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol. 1997;30:855–862
  55. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. NEJM. 1997;337:365–372
  56. Gallino A, Do DD, Alerci M, et al. Effects of probucol versus aspirin and versu brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. J Endvasc Ther. 2004;11:595–604
  57. Endo K, Miyashita Y, Sasaki H, et al. Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract. 2006;71:156–163
  58. Tardif JC, McMurray JJV, Klug E, et al. Effects of succinobucol(AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial. Lancet. 2008;371:1761–1768

PII: S0021-9150(09)00266-4

doi: 10.1016/j.atherosclerosis.2009.04.002

Atherosclerosis
Volume 207, Issue 1 , Pages 16-23 , November 2009

Article Tools

* Image Usage & Resolution